New hope for rare bone cancer: targeted pills aim to shrink tumors
NCT ID NCT07560410
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This early-stage trial tests two targeted drugs, crizotinib and alectinib, in people with a rare bone cancer that has a specific genetic change (truncated ALK). The goal is to see if these drugs can shrink or control the cancer. The study enrolls about 10 adults whose cancer has worsened after standard treatments or who have no good standard options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.